These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28512175)

  • 1. 2015/2016 Quality Risk Management Benchmarking Survey.
    Waldron K; Ramnarine E; Hartman J
    PDA J Pharm Sci Technol; 2017; 71(5):330-345. PubMed ID: 28512175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality Risk Management Competency Model-Case for the Need for QRM Competencies.
    Haddad G; Greene A
    PDA J Pharm Sci Technol; 2019; 73(4):331-344. PubMed ID: 31101709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practical discussion of risk management for manufacturing of pharmaceutical products.
    Mollah AH; Baseman HS; Long M; Rathore AS
    PDA J Pharm Sci Technol; 2014; 68(3):271-80. PubMed ID: 25188348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality management benchmarking: FDA compliance in pharmaceutical industry.
    Jochem R; Landgraf K
    Int J Health Care Qual Assur; 2010; 23(8):690-8. PubMed ID: 21125964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enabling ICH Q10 Implementation--Part 1. Striving for Excellence by Embracing ICH Q8 and ICH Q9.
    Calnan N; O'Donnell K; Greene A
    PDA J Pharm Sci Technol; 2013; 67(6):581-600. PubMed ID: 24265300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmaceutical product quality control and good manufacturing practices].
    Hiyama Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2010; (128):1-16. PubMed ID: 21381389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies.
    Demmon S; Bhargava S; Ciolek D; Halley J; Jaya N; Joubert MK; Koepf E; Smith P; Trexler-Schmidt M; Tsai P
    Biologicals; 2020 Sep; 67():9-20. PubMed ID: 32665104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proposal on How To Conduct a Biopharmaceutical Process Failure Mode and Effect Analysis (FMEA) as a Risk Assessment Tool.
    Zimmermann HF; Hentschel N
    PDA J Pharm Sci Technol; 2011; 65(5):506-12. PubMed ID: 22293839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of benchmarking in the development of biopharmaceutical products.
    Giffin M; McLeish S
    Biotechnol Annu Rev; 2003; 9():279-84. PubMed ID: 14650932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A risk-based approach to scheduling audits.
    Rönninger S; Holmes M
    PDA J Pharm Sci Technol; 2009; 63(6):575-88. PubMed ID: 20169864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality Risk Management: Putting GMP Controls First.
    O'Donnell K; Greene A; Zwitkovits M; Calnan N
    PDA J Pharm Sci Technol; 2012; 66(3):243-61. PubMed ID: 22634590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benchmarking safety pharmacology regulatory packages and best practice.
    Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
    J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality Risk Management-A Role-Based Competency Model.
    Haddad G; Greene A
    PDA J Pharm Sci Technol; 2020; 74(1):58-72. PubMed ID: 32015153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Model of Risk Analysis in Analytical Methodology for Biopharmaceutical Quality Control.
    Andrade CL; Herrera MAO; Lemes EMB
    PDA J Pharm Sci Technol; 2018; 72(3):317-331. PubMed ID: 29444996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopharmaceutical Industry Practices for Sequence Variant Analyses of Recombinant Protein Therapeutics.
    Valliere-Douglass J; Marzilli L; Deora A; Du Z; He L; Kumar SR; Liu YH; Mueller HM; Nwosu C; Stults J; Wang Y; Yaghmour S; Zhou Y
    PDA J Pharm Sci Technol; 2019; 73(6):622-634. PubMed ID: 31209169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PDA survey of quality risk management practices in the pharmaceutical, devices, & biotechnology industries.
    Ahmed R; Baseman H; Ferreira J; Genova T; Harclerode W; Hartman J; Kim S; Londeree N; Long M; Miele W; Ramjit T; Raschiatore M; Tomonto C;
    PDA J Pharm Sci Technol; 2008; 62(1):1-21. PubMed ID: 18402364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICH Q10 Pharmaceutical Quality System Guidance: Understanding Its Impact on Pharmaceutical Quality.
    VanDuyse SA; Fulford MJ; Bartlett MG
    AAPS J; 2021 Nov; 23(6):117. PubMed ID: 34773177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PCMO L01-Setting Specifications for Biological Investigational Medicinal Products.
    Krause SO
    PDA J Pharm Sci Technol; 2015; 69(5):569-89. PubMed ID: 26429107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.
    Edwards B
    Drug Saf; 2004; 27(8):609-17. PubMed ID: 15154832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Process analytical technology (PAT) for biopharmaceutical products.
    Rathore AS; Bhambure R; Ghare V
    Anal Bioanal Chem; 2010 Sep; 398(1):137-54. PubMed ID: 20480150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.